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Strengths and limitations of this study
 ► The search strategy is informed by a solid 
framework.
 ► The search will be conducted in several information 
sources.
 ► The screening/review process will be performed by 
two reviewers independently.
 ► We will not search abstracts or conference proceed-
ings specialised in machine learning.
 ► We will focus on information sources, where health- 
related outcomes are most likely to be found.
AbStrACt
Introduction Machine learning (ML) has been used in bio- 
medical research, and recently in clinical and public health 
research. However, much of the available evidence comes 
from high- income countries, where different health profiles 
challenge the application of this research to low/middle- 
income countries (LMICs). It is largely unknown what ML 
applications are available for LMICs that can support and 
advance clinical medicine and public health. We aim to 
address this gap by conducting a scoping review of health- 
related ML applications in LMICs.
Methods and analysis This scoping review will follow the 
methodology proposed by Levac et al. The search strategy 
is informed by recent systematic reviews of ML health- 
related applications. We will search Embase, Medline 
and Global Health (through Ovid), Cochrane and Google 
Scholar; we will present the date of our searches in the 
final review. Titles and abstracts will be screened by two 
reviewers independently; selected reports will be studied 
by two reviewers independently. Reports will be included if 
they are primary research where data have been analysed, 
ML techniques have been used on data from LMICs and 
they aimed to improve health- related outcomes. We will 
synthesise the information following evidence mapping 
recommendations.
Ethics and dissemination The review will provide a 
comprehensive list of health- related ML applications in 
LMICs. The results will be disseminated through scientific 
publications. We also plan to launch a website where ML 
models can be hosted so that researchers, policymakers 
and the general public can readily access them.
IntroduCtIon
Machine learning (ML) refers to the 
process through which computers, models 
or algorithms, learn and improve from data 
and processes, rather than from specific 
programmed instructions.1 2 ML can be used 
in tasks such as classification (eg, whether a 
tumour is benign or malign based on patterns 
or characteristics), clustering (eg, group 
patients with similar profiles for targeted 
prevention or treatment interventions) or 
prediction (eg, forecast propensity to risk or 
probability of outcome of a disease following 
interventions).2 Of note, there could be 
overlap across different tasks.
ML is widely used in bio- medical sciences, 
and more recently in clinical and public 
health research.3 4 Systematic reviews on 
health- related applications of ML have 
explored questions such as the accuracy of 
ML for diagnosis or outcome prediction,5–7 
but most of the research studies included in 
these reviews have come from high- income 
countries and the findings may not apply 
to low/middle- income countries (LMICs) 
because of the variability in access to health-
care and difference in the disease burden. 
It is largely unknown what ML applications 
are available for LMICs that can support 
and advance clinical medicine and public 
health.
Our aim was to address this gap in the 
evidence by conducting a scoping review of 
health- related applications of ML in LMICs to 
synthesise published evidence and to garner 
lessons to inform further research and policy 
development. The review will provide the 
first comprehensive list of health- related ML 
applications in LMICs.
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MEthodS
overview
This is a scoping review of the published scientific liter-
ature. This protocol adheres to the Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses Proto-
cols (PRISMA- P) guidelines (online supplementary 
material S1),8 and the methodology follows the proce-
dures suggested by Levac et al.9 The final publication of 
this work will adhere to the PRISMA extension Scoping 
Reviews (PRISMA- ScR) recommendations.10
PRISMA- P is a standard method to report review proto-
cols; similarly, PRSIMA- ScR is a well- known instrument to 
guide the reporting of scoping reviews. The methodology 
proposed by Levac and colleagues is useful for scoping 
reviews that aim to generate a broad picture of the avail-
able evidence on a subject.
Understanding that a key feature of scoping reviews is 
a broad research question, we aim to answer: what have 
been the health- related applications of ML techniques in 
LMICs? This review will summarise scientific evidence on 
research that have used data from LMICs for ML appli-
cations in clinical medicine (eg, risk prediction for clin-
ical decisions) and public health (eg, vector control in an 
endemic area) to provide solutions to health problems in 
LMICs.
definitions
For this work, we will follow the following definitions:
 ► LMICs: classification by the World Bank country 
income grouping (see search strategy in table 1 for a 
list of countries).11
 ► ML: analytical techniques through which computers 
learn directly from data, examples and experiences, 
rather than from a pre- programmed rule.1 2
 ► ML techniques: analytical methods within the ML 
remit, that is, where machines have learnt from data 
or processes through ML techniques or algorithms. 
These include, but are not limited to2 12: support 
vector machine, support vector regression, deci-
sion trees, random forest, neural network, Bayesian 
network, artificial neural network, computer vision 
systems, computer- assisted image processing and 
natural language processing.
Eligibility criteria
We will include scientific evidence that meets the following 
inclusion criteria (figure 1).
Primary research studies
We will include experimental and observational studies 
that have used and reported quantitative data. We will also 
screen relevant systematic reviews or narrative reviews for 
eligible primary studies and include them in our review if 
relevant. We will not include qualitative studies, opinions, 
conference abstracts, letters, editorials or any other scien-
tific work in which data have not been actively analysed 
within an ML framework.
Machine learning research should have used data from LMICs, that 
is, machine learning research that used solely data from LMICs
We will focus on ML research based on data from LMICs 
applied to LMICs. We will not include ML research that 
used data from high- income countries even though it could 
have been applied to a LMIC, and neither studies using 
LMICs data applied to high- income countries. This scoping 
review focuses on the applications of ML techniques in 
LMICs; these applications should have been developed 
using LMICs data, because prediction models and other 
algorithms work better, that is, have better accuracy, in 
the populations—data—for which they were developed. 
Conversely, when these models are applied to other popu-
lations, settings or data, they need some modification (eg, 
recalibration). We will also exclude studies that have used 
LMIC data in a consortium or data pooling group if the 
model or results cannot be separated for the LMIC alone; in 
other words, we will exclude a report if this used LMIC data 
in aggregate with data from high- income countries, but the 
application cannot be separated for the LMIC alone.
Models developed in sites other than LMICs may not 
work correctly in these countries. For example, projects with 
digital imaging from high- income countries may reflect a 
different scenario; that is, images from streets in LMICs may 
depict objects or features not found in high- income coun-
tries. Another example could be projects for sound/noise 
classification. Those from high- income countries may not 
identify the variety of noises usually available in LIMCs (eg, 
loud cars or indiscriminate use of car horns). Finally, LMICs 
still have sizeable rural areas with large populations. Extrap-
olating models built for highly urbanised cities may not be 
adequate for rural sites.
Examples of studies of interest include: (1) develop-
ment of a ‘deep learning- based visual evaluation algo-
rithm’ to early identify cervical cancer signs based on data 
from women in Costa Rica,13 (2) classification of free- text 
(random forest) in emergency department records from 
nine hospitals in Nicaragua14 and (3) automatic classifica-
tion (neural networks) of paediatric pneumonia based on 
ultrasound records from children in Peru.15
Distinguishing between ML applications and more 
conventional statistical methods could be challenging 
because in some cases the definitions are unclear, for 
instance, regression analysis. Nonetheless, from the 
context of the scientific paper, from the aims or overall 
methodological approach, it is possible to reckon 
whether a study uses ML techniques versus more conven-
tional statistical methods. If needed, we would reach out 
to authors for further information.
The outcome of the study/analysis was to improve a health-related 
outcome
The primary outcome of the selected studies should have 
sought improvements in the following health- related 
endpoints along the care cascade: diagnosis, treatment, 
control, survival, complications and mortality. These 
outcomes have been selected because of their relevance 
in healthcare, clinical medicine and public health. As 
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Table 1 Overall search terms
1 artificial intelligence.mp.
2 exp Artificial Intelligence/
3 machine learning.mp.
4 exp machine learning/
5 deep learning.mp.
6 unsupervised machine learning.mp.
7 supervised machine learning.mp.
8 computational Intelligence.mp.
9 predictive analytic*.mp.
10 support vector machine.mp.
11 support vector regression.mp.
12 decision tree*.mp.
13 random forest.mp.
14 neural network*.mp.
15 exp Neural Networks/
16 bayesian network*.mp.
17 artificial neural network*.mp.
18 convolutional neural network*.mp.
19 computer vision systems.mp.
20 exp Image Processing, Computer- Assisted/
21 natural language processesing.mp.
22 1 or 2 or 3 …or 21
23 ((“Afghanistan”) or (“Benin”) or (“Burkina Faso”) or (“Burundi”) or (“Central African Republic”) or (“Chad”) or (“Comoros”) or (“Democratic 
Republic of the Congo”) or (“Eritrea”) or (“Ethiopia”) or (“Gambia”) or (“Guinea”) or (“Guinea- Bissau”) or (“Haiti”) or (“Democratic 
People's Republic of Korea”) or (“Liberia”) or (“Madagascar”) or (“Malawi”) or (“Mali”) or (“Mozambique”) or (“Nepal”) or (“Niger”) or 
(“Rwanda”) or (“Senegal”) or (“Sierra Leone”) or (“Somalia”) or (“South Sudan”) or (“Tanzania”) or (“Togo”) or (“Uganda”) or (“Zimbabwe”) 
or (“Armenia”) or (“Bangladesh”) or (“Bhutan”) or (“Bolivia”) or (“Cape Verde”) or (“Cambodia”) or (“Cameroon”) or (“Congo”) or (“Cote 
d'Ivoire”) or (“Djibouti”) or (“Egypt”) or (“El Salvador”) or (“Ghana”) or (“Guatemala”) or (“Honduras”) or (“India”) or (“Indonesia”) or 
(“Kenya”) or (“Micronesia”) or (“Kosovo”) or (“Kyrgyzstan”) or (“Laos”) or (“Lesotho”) or (“Mauritania”) or (“Moldova”) or (“Mongolia”) 
or (“Morocco”) or (“Myanmar”) or (“Nicaragua”) or (“Nigeria”) or (“Pakistan”) or (“Papua New Guinea”) or (“Philippines”) or (“Samoa”) 
or (“Atlantic Islands”) or (“Melanesia”) or (“Sri Lanka”) or (“Sudan”) or (“Swaziland”) or (“Syria”) or (“Tajikistan”) or (“Timor- Leste”) or 
(“Tonga”) or (“Tunisia”) or (“Ukraine”) or (“Uzbekistan”) or (“Vanuatu”) or (“Vietnam”) or (“Middle East”) or (“Yemen”) or (“Zambia”) or 
(“Albania”) or (“Algeria”) or (“American Samoa”) or (“Angola”) or (“Argentina”) or (“Azerbaijan”) or (“Republic of Belarus”) or (“Belize”) 
or (“Bosnia and Herzegovina”) or (“Botswana”) or (“Brazil”) or (“Bulgaria”) or (“China”) or (“Colombia”) or (“Costa Rica”) or (“Cuba”) or 
(“Dominica”) or (“Dominican Republic”) or (“Equatorial Guinea”) or (“Ecuador”) or (“Fiji”) or (“Gabon”) or (“Georgia”) or (“Grenada”) or 
(“Guyana”) or (“Iran”) or (“Iraq”) or (“Jamaica”) or (“Jordan”) or (“Kazakhstan”) or (“Lebanon”) or (“Libya”) or (“Macedonia (Republic)”) 
or (“Malaysia”) or (“Indian Ocean Islands”) or (“Mauritius”) or (“Mexico”) or (“Montenegro”) or (“Namibia”) or (“Palau”) or (“Panama”) 
or (“Paraguay”) or (“Peru”) or (“Romania”) or (“Russia”) or (“Serbia”) or (“South Africa”) or (“Saint Lucia”) or (“Saint Vincent and the 
Grenadines”) or (“Suriname”) or (“Thailand”) or (“Turkey”) or (“Turkmenistan”) or (“Venezuela”) or (developing countr) or (low- income 
countr*) or (middle- income countr*) or (low- middle income countr*) or (upper- middle income countr*))
24 22 and 23
25 exp animals/ not humans.sh.
26 24 not 25
27 Remove duplicates from 26
secondary outcome, we will also include studies that have 
reported endpoints related to cost, efficiency and produc-
tivity in the healthcare process.
Information sources
We will conduct the search in three databases through 
Ovid: Embase, Medline and Global Health; in addition, 
we will search Cochrane and Google Scholar (first 10 
pages). Besides Google Scholar, no other grey litera-
ture source will be searched. These sources will be used 
without language or time/year restrictions. We have a 
very diverse team covering many languages and we will 
tap into our networks at our institutions in case we come 
across a study in a language that the authors do not speak.
Search strategy
Based on recent systematic reviews of ML applications on 
health- related endpoints: outcome prediction in gastroin-
testinal bleeding,7 assessment of physicians knowledge,16 
applications on genomic data to predict outcomes in 
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Figure 1 Algorithm to filter search results.
cancer patients17 and available ML algorithms to improve 
genomic data analysis,18 we developed our search strategy 
(table 1). We will screen the references of the included 
reports for any other relevant studies.
Study records
Results will be downloaded into EndNote, where dupli-
cates will be omitted, and a second cleaning of duplicated 
results will be conducted using the online tool Rayyan.19 
Titles and abstracts will be reviewed by two independent 
researchers following the above detailed selection criteria 
(figure 1); discrepancies will be solved by consensus or 
by a third party. Selected titles will be sought in full text, 
which will be assessed by two independent reviewers 
following the same selection criteria (figure 1). Again, in 
case of conflicts, these will be solved by consensus or by a 
third party.
data collection
The reviewers will decide on a list of items that will be 
extracted to successfully answer the research question. 
These items will be implemented in an Excel spreadsheet 
before data extraction and will not be modified after-
wards. Information of interest includes: country of origin; 
analytical approach; type of data used; data source; model 
performance; outcome of interest; number of observa-
tions and whether the model is available for independent 
use or reproduction. Data from the selected reports will 
be extracted by two researchers independently; if there 
were discrepancies, these will be solved by consensus 
among them or by a third party.
risk of bias in individual studies
Because this is a scoping review aiming to summarise 
available evidence to identify research gaps and potential 
uses of ML to improve health- related outcomes in LMICs, 
no risk of bias of individual studies is planned.
data synthesis
We anticipate a large heterogeneity of selected reports, 
both in terms of methodology and outcomes, as well as 
target population and data sources. Therefore, no meta- 
analysis is planned and only a qualitative summary will 
be conducted. Following current recommendations for 
scoping reviews and evidence mapping,20 we will present 
the results through tables and figures, for example, a 
map pointing out where studies have been conducted 
and summarising key characteristics. As needed, we will 
consider other figures such as a matrix evidence.20
Ethics and dissemination
This scoping review will not require ethical approval 
because it did not study human subjects; also, it included 
sources that are or can be made available to the public.
We plan to report our findings in a scientific publica-
tion. In addition, and depending on available resources, 
we aim to produce a website (or implement in an existing 
website) in which the findings and summarised reports 
can be easily accessed. Furthermore, we aim to host the 
ML models so that researchers, policymakers and the 
general public can readily access them. Where the ML 
models are open access or can be accessed through the 
original reports, these will be hosted on the website or a 
link to the original source will be provided; conversely, 
where ML models are not open access, we will contact 
the study authors and ask for the model to be hosted in 
our website or for a link to their ML model. This dissem-
ination plan aims to increase visibility of ML research 
in LMICs and to increase the use of available models, 
thereby encouraging further research to improve health 
outcomes. We will engage with the communication office 
in our universities to promote this website through rele-
vant channels, including but not limited to social media, 
newsletters and institutional websites.
Patient and public involvement
No patients will be directly involved in the design, plan-
ning and conception of this study.
Author affiliations
1Department of Epidemiology and Biostatistics, School of Public Health, Imperial 
College London, London, UK
2CRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana 
Cayetano Heredia, Lima, Peru
3Family Medicine and Primary Care, Lee Kong Chian School of Medicine, Nanyang 
Technological University, Singapore
4Department of Primary Care and Public Health, School of Public Health, Imperial 
College London, London, UK
5Department of Epidemiology and Biostatistics and MRC- PHE Centre for 
Environment and Health, School of Public Health, Imperial College London, London, 
UK
6Wellframe Inc, Boston, Massachusetts, USA
7Facultad de Medicina "Alberto Hurtado", Universidad Peruana Cayetano Heredia, 
Lima, Peru
8Harvard T.H Chan School of Public Health and Harvard Medical School, Harvard 
University, Cambridge, Massachusetts, USA
Contributors RMC- L conceived the idea and drafted the manuscript. JP- S, TP 
and RA provided advice to improve the research question and LTC to improve the 
5Carrillo- Larco RM, et al. BMJ Open 2020;10:e035983. doi:10.1136/bmjopen-2019-035983
Open access
protocol. JJM and RA edited and provided insights to improve the protocol. All 
authors approved the submitted version.
Funding RMC- L has been supported by a Strategic Award, Wellcome Trust- Imperial 
College Centre for Global Health Research (100693/Z/12/Z) and Imperial College 
London Wellcome Trust Institutional Strategic Support Fund (Global Health Clinical 
Research Training Fellowship) (294834/Z/16/Z ISSF ICL). RMC- L is supported by a 
Wellcome Trust International Training Fellowship (214185/Z/18/Z). The funders had 
no role in this work and decision to submit for publication.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in 
the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
orCId ids
Rodrigo M Carrillo- Larco http:// orcid. org/ 0000- 0002- 2090- 1856
J Jaime Miranda http:// orcid. org/ 0000- 0002- 4738- 5468
rEFErEnCES
 1 Davies SC. Annual report of the chief medical officer, 2018 health 
2040 – better health within reach. Department of Health and Social 
Care, 2018.
 2 Rebala G, Ravi A, Churiwala S. An introduction to machine learning. 
Springer International Publishing, 2019.
 3 Panch T, Pearson- Stuttard J, Greaves F, et al. Artificial intelligence: 
opportunities and risks for public health. Lancet Digit Health 
2019;1:e13–14.
 4 Wahl B, Cossy- Gantner A, Germann S, et al. Artificial intelligence (AI) 
and global health: how can AI contribute to health in resource- poor 
settings? BMJ Glob Health 2018;3:e000798.
 5 de Filippis R, Carbone EA, Gaetano R, et al. Machine learning 
techniques in a structural and functional MRI diagnostic approach 
in schizophrenia: a systematic review. Neuropsychiatr Dis Treat 
2019;15:1605–27.
 6 Bradley A, van der Meer R, McKay C. Personalized pancreatic 
cancer management: a systematic review of how machine learning is 
supporting decision- making. Pancreas 2019;48:598–604.
 7 Shung D, Simonov M, Gentry M, et al. Machine learning to predict 
outcomes in patients with acute gastrointestinal bleeding: a 
systematic review. Dig Dis Sci 2019;64:2078–87.
 8 Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for 
systematic review and meta- analysis protocols (PRISMA- P) 2015: 
elaboration and explanation. BMJ 2015;349:g7647.
 9 Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the 
methodology. Implement Sci 2010;5:69.
 10 Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping 
reviews (PRISMA- ScR): checklist and explanation. Ann Intern Med 
2018;169:467–73.
 11 The World Bank. World bank country and lending groups. Available: 
https:// datahelpdesk. worldbank. org/ knowledgebase/ articles/ 906519- 
world- bank- country- and- lending- groups
 12 Burkov A. The Hundred- page machine learning book, 2019.
 13 Hu L, Bell D, Antani S, et al. An observational study of deep learning 
and automated evaluation of cervical images for cancer screening. J 
Natl Cancer Inst 2019;111:923–32.
 14 Lorenzoni G, Bressan S, Lanera C, et al. Analysis of unstructured 
Text- Based data using machine learning techniques: the case of 
pediatric emergency department records in Nicaragua. Med Care 
Res Rev 2019;20:107755871984412.
 15 Correa M, Zimic M, Barrientos F, et al. Automatic classification of 
pediatric pneumonia based on lung ultrasound pattern recognition. 
PLoS One 2018;13:e0206410.
 16 Dias RD, Gupta A, Yule SJ. Using machine learning to assess 
physician competence: a systematic review. Acad Med 
2019;94:427–39.
 17 Patil S, Habib Awan K, Arakeri G, et al. Machine learning and its 
potential applications to the genomic study of head and neck 
cancer- a systematic review. J Oral Pathol Med 2019;48:773–9.
 18 Wu J, Zhao Y. Machine learning technology in the application of 
genome analysis: a systematic review. Gene 2019;705:149–56.
 19 Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan- a web and 
mobile APP for systematic reviews. Syst Rev 2016;5:210.
 20 Evidence and gap maps: a comparison of different approaches. 
Oslo, Norway: the Campbell collaboration. Available: www. camp bell 
coll abor ation. org/
